-

International Organization of Vine and Wine (OIV) Officially Incorporates NMR Method in Compendium of International Methods of Analysis of Wines and Musts

ETTLINGEN, Germany--(BUSINESS WIRE)--Nuclear magnetic resonance (NMR) spectroscopy has been incorporated by the intergovernmental and International Organization of Vine and Wine (OIV) in its compendium of International Methods of Analysis of Wines and Musts, for the quantification of six key parameters in wine – glucose, malic acid, acetic acid, fumaric acid, shikimic acid and sorbic acid.

Traditionally, several analytical techniques with individual calibrations are needed to measure these parameters. Now, 1H-NMR can very accurately quantify a significantly higher number of compounds in wines – simultaneously, label-free and with a single calibration.

The advent of advanced techniques like 1H-NMR helps to complete the chain of authenticity in high-end wine supply chains. The 1H-NMR fingerprint contains hundreds of signals that, when combined with sophisticated statistics, allows the creation of robust databases, providing a reference for the contents, varietals, and regions of production of wines.

Bruker’s NMR Wine-Profiling™ 4.0 module is based on the 400 MHz NMR FoodScreener™ platform. Now, 1H-NMR profiling has been accepted by the OIV, and offers the direct, label-free quantification of 53 compounds in a single, automated measurement. This enables the verification of geographical origin, grape variety of monovarietal wines, and quality grade, e.g., of Spanish red wines. This addresses the increasing demand for assurance of the origin and integrity of wine from the vineyard to the point of sale, enhancing supply chain surveillance and protecting valuable brands.

Elena Meléndez Álvarez, Director at the Estación Enológica de Haro, La Rioja, Spain, commented: “The versatility of this equipment makes it possible to adapt the analyses to our client´s specific needs. A single analysis is enough to obtain information about over 50 wine metabolites. Until now, a wine laboratory would have had to use a combination of various methods to arrive at similar results. The NMR Wine-Profiling™ 4.0 module gives an overall view of the wine's main components, such as acidity and alcohol content and of minor ones, like polyphenols and amino acids.”

Dr. Iris Mangelschots, President of Bruker BioSpin’s Applied, Industrial and Clinical Division, commented: “The announcement of 1H-NMR as an official OIV method is an important step forward for the wine industry, and Bruker is proud to contribute high-value solutions that lead the way. Robust, quantitative wine-profiling by 1H-NMR is an easy-to-use, rapid and reliable test that provides growers and producers with the assurance of an authentication method to detect adulteration or fraud.”

Following this major milestone in NMR-based wine profiling, Bruker continues to innovate in NMR and is developing advanced food analysis solutions based on the principles of blockchain to identify adulteration in high value products such as honey, juice, spices and olive oil.

About the International Organization of Vine and Wine

The scientific and technical reference of the vine and wine world, the OIV is an intergovernmental organisation of a scientific and technical nature of recognised competence for its works concerning vines, wine, wine-based beverages, table grapes, raisins and other vine-based products. OIV’s standards are adopted by many wine producing countries. For more information, please visit: https://www.oiv.int/en/ or https://www.oiv.int/public/medias/7590/oiv-oeno-618-2020-en.pdf

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Customer Contact:
Lea Heintz
Product Manager
Bruker BioSpin AIC Division
T: +49 721 5161- 0
E: lea.heintz@bruker.com

Media Contact:
Thorsten Thiel
VP of Group Marketing
Bruker BioSpin Group
T: +49 721 5161-6500
E: thorsten.thiel@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions

Contacts

Customer Contact:
Lea Heintz
Product Manager
Bruker BioSpin AIC Division
T: +49 721 5161- 0
E: lea.heintz@bruker.com

Media Contact:
Thorsten Thiel
VP of Group Marketing
Bruker BioSpin Group
T: +49 721 5161-6500
E: thorsten.thiel@bruker.com

More News From Bruker Corporation

Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

HANAU, Germany--(BUSINESS WIRE)--The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (Nasdaq: BRKR), today announced two multi-year supply agreements for Bruker’s latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration pe...

Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

THUN, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of an additional 60% ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker’s ownership to 100%. The transaction adds ultra-fast TOF-MS technology for small-molecule markets, including atmospheric chemistry research, air quality monitoring, exposomics, foods, flavors &a...

Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events...
Back to Newsroom